Pumecitinib

CAS No. 2401057-12-1

Pumecitinib( —— )

Catalog No. M35964 CAS No. 2401057-12-1

Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 50 In Stock
5MG 42 In Stock
10MG 67 In Stock
25MG 124 In Stock
50MG 193 In Stock
100MG 275 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pumecitinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.
  • Description
    Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2401057-12-1
  • Formula Weight
    400.46
  • Molecular Formula
    C17H20N8O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (312.14 mM; Ultrasonic (<60°C)
  • SMILES
    CC(C)S(=O)(=O)N1CC(CC#N)(C1)n1cc(c(N)n1)-c1ncnc2[nH]ccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. WHO Drug Information-World Health Organization (WHO).
molnova catalog
related products
  • Tofacitinib citrate

    A potent, specific, orally active inhibitor of JAK3 with IC50 of 1 nM in cell-free assays; displays 20- to 100-fold less potency for JAK2 and JAK1 (IC50=20 nM and 112 nM, respectively).

  • WYE-151650

    WYE-151650 is a novel potent, selective JAK3 inhibitor with IC50 of 0.8 nM, displays 36-, 14-, and 34-fold selectivity against JAK-1, JAK-2, and Tyk-2, respectively.

  • Ruxolitinib phosphat...

    A potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.